(Q38023813)

27 August 2017

Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses (English)

1 reference

27 August 2017

1 reference

1

Michael P Bogenschutz

0 references

author name string

Jessica M Pommy

series ordinal

2

1 reference

PubMed ID

22761106

27 August 2017

language of work or name

1 reference

4 July 2012

1 reference

Drug Testing and Analysis

27 August 2017

1 reference

27 August 2017

4

1 reference

27 August 2017

7-8

1 reference

27 August 2017

543-555

1 reference

27 August 2017

1 reference

Long Lasting Effects of LSD on Normals

21 January 2018

1 reference

Treatment of alcoholism using psychedelic drugs: a review of the program of research

21 January 2018

1 reference

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

21 January 2018

1 reference

Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders

21 January 2018

1 reference

A Controlled Comparison of Lysergic Acid Diethylamide (LSD) and Dextroamphetamine in Alcoholics

21 January 2018

1 reference

A clinical study of LSD treatment in alcoholism

21 January 2018

1 reference

Psychedelics and the human receptorome

21 January 2018

1 reference

The behavioral pharmacology of hallucinogens

21 January 2018

1 reference

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

21 January 2018

1 reference

In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents

21 January 2018

1 reference

Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex

21 January 2018

1 reference

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

21 January 2018

1 reference

AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes

21 January 2018

1 reference

Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo

21 January 2018

1 reference

Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo

21 January 2018

1 reference

Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior

21 January 2018

1 reference

Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists

21 January 2018

1 reference

5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.

21 January 2018

1 reference

Serotonin (5-HT) induces glial cell line-derived neurotrophic factor (GDNF) mRNA expression via the transactivation of fibroblast growth factor receptor 2 (FGFR2) in rat C6 glioma cells

21 January 2018

1 reference

Role of BDNF and GDNF in drug reward and relapse: a review

21 January 2018

1 reference

Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex

21 January 2018

1 reference

Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling

21 January 2018

1 reference

REACTIONS TO PSILOCYBJN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT

21 January 2018

1 reference

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

21 January 2018

1 reference

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

21 January 2018

1 reference

The Construction and Preliminary Validation of a Measure of Reported Mystical Experience

21 January 2018

1 reference

Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans

21 January 2018

1 reference

Report on psychoactive drug use among adolescents using ayahuasca within a religious context

21 January 2018

1 reference

Assessment of addiction severity among ritual users of ayahuasca

21 January 2018

1 reference

Changes in spirituality among ayahuasca ceremony novice participants

21 January 2018

1 reference

Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas

21 January 2018

1 reference

Jesus, peyote, and the holy people: alcohol abuse and the ethos of power in Navajo healing

21 January 2018

1 reference

Psychological and cognitive effects of long-term peyote use among Native Americans

21 January 2018

1 reference

The phenomenon of quantum change.

21 January 2018

1 reference

De profundis: spiritual transformations in Alcoholics Anonymous.

21 January 2018

1 reference

A role for spiritual change in the benefits of 12-step involvement

21 January 2018

1 reference

Spirituality in recovery: a lagged mediational analysis of alcoholics anonymous' principal theoretical mechanism of behavior change

21 January 2018

1 reference

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

21 January 2018

1 reference

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

21 January 2018

1 reference

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression

21 January 2018

1 reference

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial

21 January 2018

1 reference

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression

21 January 2018

1 reference

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

21 January 2018

1 reference

The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects

21 January 2018

1 reference

Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist

21 January 2018

1 reference

Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons

21 January 2018

1 reference

A review of the acute subjective effects of MDMA/ecstasy

21 January 2018

1 reference

A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers

21 January 2018

1 reference

Hallucinogenic drugs and plants in psychotherapy and shamanism

21 January 2018

1 reference

The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study

21 January 2018

1 reference

Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions

21 January 2018

1 reference

Temporal sequencing of lifetime mood disorders in relation to comorbid anxiety and substance use disorders--findings from the Netherlands Mental Health Survey and Incidence Study

21 January 2018

1 reference

Comorbidity and temporal ordering of alcohol use disorders and other psychiatric disorders: results from a Danish register-based study

21 January 2018

1 reference

Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions

21 January 2018

1 reference

Exploratory findings from the Reasons for Drinking Questionnaire

21 January 2018

1 reference

Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence

21 January 2018

1 reference

Treatment of cocaine dependence and depression

21 January 2018

1 reference

Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis.

21 January 2018

1 reference

Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis

21 January 2018

1 reference

Efficacy of buspirone in alcohol dependence: a review

21 January 2018

1 reference

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

21 January 2018

1 reference

Alcohol involvement and the Five-Factor model of personality: a meta-analysis

21 January 2018

1 reference

Linking "big" personality traits to anxiety, depressive, and substance use disorders: a meta-analysis

21 January 2018

1 reference

The relationship of NEO-PI performance to coping styles, patterns of use, and triggers for use among substance abusers.

21 January 2018

1 reference

Five-Factor Model personality profiles of drug users

21 January 2018

1 reference

Big Five factors of personality and replicated predictions of behavior

21 January 2018

1 reference

A personality-based description of maturing out of alcohol problems: extension with a five-factor model and robustness to modeling challenges

21 January 2018

1 reference

Personality changes in women recovering from substance-related dependence.

21 January 2018

1 reference

Relationship between craving and personality in treatment-seeking women with substance-related disorders

21 January 2018

1 reference

Relations between personality and coping: A meta-analysis

21 January 2018

1 reference

Determining the relative importance of the mechanisms of behavior change within Alcoholics Anonymous: a multiple mediator analysis

21 January 2018

1 reference

Craving and relapse measurement in alcoholism

21 January 2018

1 reference

Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse

21 January 2018

1 reference

Imaging stress- and cue-induced drug and alcohol craving: association with relapse and clinical implications

21 January 2018

1 reference

Daily ratings measures of alcohol craving during an inpatient stay define subtypes of alcohol addiction that predict subsequent risk for resumption of drinking.

21 January 2018

1 reference

Reactivity to laboratory stress provocation predicts relapse to cocaine

21 January 2018

1 reference

Relationship of relapse with impulsivity, novelty seeking and craving in male alcohol-dependent inpatients.

21 January 2018

1 reference

Dynamic effects of craving and negative affect on adolescent smoking relapse.

21 January 2018

1 reference

Role of the serotonergic system in alcohol dependence: from animal models to clinics

21 January 2018

1 reference

Brain dopamine response in human opioid addiction.

21 January 2018

1 reference

Heterogeneous effects of alcohol on dopamine release in the striatum: a PET study.

21 January 2018

1 reference

Drug craving and addiction: integrating psychological and neuropsychopharmacological approaches.

21 January 2018

1 reference

Effects of lowered serotonin transmission on cocaine-induced striatal dopamine response: PET [¹¹C]raclopride study in humans.

21 January 2018

1 reference

Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings

21 January 2018

1 reference

5-HT receptors and reward-related behaviour: a review.

21 January 2018

1 reference

The role of serotonin in craving: from basic research to human studies

21 January 2018

1 reference

Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers

21 January 2018

1 reference

Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking

21 January 2018

1 reference

Ondansetron reduces the craving of biologically predisposed alcoholics

21 January 2018

1 reference

Self-efficacy: toward a unifying theory of behavioral change

21 January 2018

1 reference

The role of self-efficacy in the treatment of substance use disorders

21 January 2018

1 reference

A comparison of general self-efficacy and drinking refusal self-efficacy in predicting drinking behavior.

21 January 2018

1 reference

Cognitive consequences of forced compliance

21 January 2018

1 reference

From in-session behaviors to drinking outcomes: a causal chain for motivational interviewing.

21 January 2018

1 reference

Medication development of ibogaine as a pharmacotherapy for drug dependence.

21 January 2018

1 reference

Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review

21 January 2018

1 reference

Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption

21 January 2018

1 reference

Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration

21 January 2018

1 reference

Positive autoregulation of GDNF levels in the ventral tegmental area mediates long-lasting inhibition of excessive alcohol consumption

21 January 2018

1 reference

GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse

21 January 2018

1 reference

GDNF--a potential target to treat addiction

21 January 2018

1 reference

The Combination of Psychedelic and Aversive Approaches in Alcoholism Treatment

21 January 2018

1 reference

Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up

21 January 2018

1 reference

Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence

21 January 2018

1 reference

Human hallucinogen research: guidelines for safety

21 January 2018

1 reference

The Role of Religion, Spirituality and Alcoholics Anonymous in Sustained Sobriety

21 January 2018

1 reference

Life-Changing Experiences, Spirituality and Religiousness of Persons Entering Treatment for Alcohol Problems

21 January 2018

1 reference

Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems

21 January 2018

1 reference

Mescaline, LSD, psilocybin, and personality change

21 January 2018

1 reference

7 January 2021

Personality Change in LSD Users

1 reference

7 January 2021

Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study

1 reference

7 January 2021

Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study

1 reference

7 January 2021

5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex.

1 reference

7 January 2021

REACTIONS TO PSILOCYBIN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT.

1 reference

7 January 2021

Peyote in the treatment of alcoholism among American Indians

1 reference

7 January 2021

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.

1 reference

7 January 2021

Negative affect, relapse, and Alcoholics Anonymous (AA): does AA work by reducing anger?

1 reference

7 January 2021

Impact of different personality dimensions (NEO Five-Factor Inventory) on the outcome of alcohol-dependent patients 6 and 12 months after treatment

1 reference

7 January 2021

Cocaine craving as a predictor of treatment attrition and outcomes after residential treatment for cocaine dependence.

1 reference

7 January 2021

Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics

1 reference

7 January 2021

A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment

1 reference

7 January 2021

Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial

1 reference

7 January 2021

Fluoxetine attenuates alcohol intake and desire to drink

1 reference

7 January 2021

Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers.

1 reference

7 January 2021

Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial

1 reference

7 January 2021

Examining the effects of alcoholism typology and AA attendance on self-efficacy as a mechanism of change.

1 reference

7 January 2021

What is Motivational Interviewing?

1 reference

7 January 2021

Development of novel medications for drug addiction. The legacy of an African shrub.

1 reference

7 January 2021

The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity.

1 reference

7 January 2021

Alcohol treatment, changes in coping skills, self-efficacy, and levels of alcohol use and related problems 1 year following treatment initiation

1 reference

7 January 2021

Identifiers

DOI

10.1002/DTA.1376

1 reference

27 August 2017

1 reference

PubMed ID

22761106